Hacker News Reader

Comment by forum_ghost | Hacker News Reader

Failed in clinical trials? Never heard about this until now.

„The CYPRESS clinical study3 enrolled, randomized, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada. At the time of enrollment, subjects were six to 10 years old having myopia between -0.75 D and -4.50 D.

After two years of wear, 85% of children wearing the innovative spectacle lenses showed less than one diopter of myopia progression.4 Moreover, the study also showed that 41% of the children wearing spectacle lenses with Diffusion Optics Technology™ showed no clinically meaningful progression in refractive error after two years versus only 17% in the control group.5“

See https://www.coopervisionsec.eu/news-two-year-clinical-trial-...

Update Jan. 20, 2021: The North America myopia trial is nearing the end of its second year and it is closed to enrollment. Based on the one-year data, the eyeglasses have regulatory approval to be sold as medical devices in Europe and Canada. They are currently being sold in Canada under the brand name "Kikko." Researchers anticipate regulatory approval in the United States in about a year that will be based on the two-year results. People can go to the Kikko website https://kikkovision.com/ and sign up to receive updates about U.S. availability. Once they are approved in the U.S., people will be able to buy the glasses from their optometrist or ophthalmologist.